Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV ...Middle East

TITUSVILLE, N.J., Jan. 21, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen's rilpivirine and ViiV Healthcare's cabotegravir), the first and only...

Hence then, the article about janssen announces u s fda approval of cabenuva rilpivirine and cabotegravir the first long acting regimen for the treatment of hiv was published today ( Friday 22/01/2021 - 07:15 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV )

Also on site :

• Meta Removes Muse Image AI Feature After Backlash: “Missed The Mark”
• Walmart's 'Sleek' $54 Metal-Frame Sling Chair Gives Your Home West Elm Vibes for a Fraction of the Price
• Morgan Spector In Talks To Play Robert Langdon, Rebecca Hall Eyed As Female Lead In Netflix Series Based On Dan Brown’s ‘The Secret of Secrets’